Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4

December 16, 2014

December 1	0, 2011										
FORM	Л Д								OMB AF	PPROVAL	
	Washington, D.C. 205					ANGE C	OMMISSION	OMB Number:	3235-0287		
Check the if no lon	ger								Expires:	January 31, 2005	
subject to	MENT OF	CHAN			ICIA	AL OWN	NERSHIP OF	Estimated a			
Section				SECUE	RITIES				burden hou	rs per	
Form 4 o		ement to S	laction 1	6(a) of th	a Saguri	tios I	Evolongo	Act of 1934,	response	0.5	
obligatio	ons Section 170						_	1935 or Section	1		
may con See Instr	unue.			vestment	_	-	•		•		
1(b).	uction	()			•						
(Print or Type	Responses)										
1. Name and Address of Reporting Person * 2. 1 Silva Paul M Sym			2. Issue	r Name an o	l Ticker o	r Tradi	ino	5. Relationship of Reporting Person(s) to			
			2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS					Issuer			
								(Check all applicable)			
			INC / MA [VRTX]					(Check all applicable)			
(Last)	(First) (I	Middle)	3. Date of	f Earliest T	ransaction			Director		Owner	
C/O VERTEX PHARMACEUTICALS			(Month/Day/Year) 12/12/2014					_X_ Officer (give below)	er (specify		
								SVP & Corp Controller			
	RATED, 50 NOR	THERN									
AVENUE	MITED, 50 NOK	TILKI									
	(Street)		4 If Ame	endment, Da	ate Origin:	al		6. Individual or Jo	int/Group Filin	o(Check	
				nth/Day/Yea	_			Applicable Line)	ing Group 1 iiii	B(cinetii	
								X Form filed by O Form filed by M			
BOSTON,	MA 02210							Person	ole man One Ke	porting	
(City)	(State)	(Zip)	Tabl	le I - Non-I	Derivative	Secu	rities Acqu	iired, Disposed of	, or Beneficial	ly Owned	
1.Title of	2. Transaction Date			3.	4. Securi			5. Amount of	6.	7. Nature of	
Security (Instr. 3)	(Month/Day/Year)	Execution any	Date, 1f	Transactio Code	on(A) or D (Instr. 3,			Securities Beneficially	Ownership Form: Direct	Indirect Beneficial	
(111311. 3)			ay/Year)	(Instr. 8)	(msu. 5,	i una	. 3)	Owned	(D) or	Ownership	
								Following	Indirect (I)	(Instr. 4)	
						(A)		Reported Transaction(s)	(Instr. 4)		
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
C				Code v	rimount	(D)	\$				
Common Stock	12/12/2014			S(1)	1,713	D	119.82	15,287	D		
SIOCK							(2) (3)				
C							\$				
Common Stock	12/12/2014			S(1)	1,100	D	120.48	14,187	D		
Stock							(3) (4)				
Common								160	T	40171-	
Stock								169	I	401(k)	

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5.		6. Date Exercisable and		7. Tit	le and	8. Price of	1
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionNumber		Expiration Date		Amou	int of	Derivative	
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	rlying	Security	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8) Derivativ	e		Secur	ities	(Instr. 5)	į
	Derivative				Securities	;		(Instr.	. 3 and 4)		
	Security				Acquired						1
					(A) or						1
					Disposed						
					of (D)						
					(Instr. 3,						
					4, and 5)						
									A		
									Amount		
						Date	Expiration	m: .1	or		
						Exercisable	•		Number		
				~					of		
				Code \	(A) (D)				Shares		

Reporting Owners

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

Silva Paul M C/O VERTEX PHARMACEUTICALS INCORPORATED **50 NORTHERN AVENUE** BOSTON, MA 02210

SVP & Corp Controller

Signatures

Kenneth L. Horton, 12/16/2014 Attorney-In-Fact

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$119.82 (range \$119.20 to \$120.19).
- Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Open market sales reported on this line occurred at a weighted average price of \$120.48 (range \$120.28 to \$120.84).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners 2

9. Ni Deriv

SEC 1474

(9-02)

Secu Bene

Follo Repo Trans (Insti

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.